Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2013 Results
Date:5/9/2013

57,250(1)  Unaudited(2)  Non-cash stock-based compensation is allocated to both Research & development and General & administrative expenses OPERATIONAL HIGHLIGHTSOn March 25, 2013, Vanda announced that it held a pre-NDA meeting with the Division of Neurology Products of the FDA to discuss the regulatory path for filing an NDA for tasimelteon, a circadian regulator, for the treatment of Non-24.  At the pre-NDA meeting, the FDA confirmed that the efficacy and safety data proposed by Vanda to be submitted in the tasimelteon NDA for Non-24 is adequate to support filing.  The NDA supporting package that includes data from clinical pharmacology, pre-clinical pharmacology program, chemistry and manufacturing was also deemed adequate to support filing. Based on this successful completion of the pre-NDA meeting, Vanda is targeting an NDA submission for tasimelteon in mid-2013.  Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals.  Currently there is no FDA approved treatment for Non-24. 

Vanda continues to expand its activities in support of Non-24 disease awareness and education with professional, advocacy and patient groups.  In June 2013, Vanda will present data from the SET and RESET studies at the 27th Annual Meeting of the Associated Professional Sleep Societies, SLEEP 2013, and the 95th Annual Endocrine Society Meeting, ENDO 2013.  In addition, Vanda continues to build its registry of individuals who have the potential to be Non-24 patients.
The U.S. based registry has over 1,500 individuals and was created to facilitate the recruitment of patients for the tasimelteon Non-24 clinical studies. 

On April 25, 2013, Vanda and Bristol-Myers Squibb (BMS) entered into an amendment to the tasimelteon licensing agreement.  Subsequent to this amendment, BMS waived its option to re-acquire rights to develop and commercialize tasimelteon in count
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
2. Nieuwe behandeloptie vandaag geïntroduceerd voor artsen die patiënten behandelen met veelvuldig recidiverend of refractair agressief B-cel-non-hodgkinlymfoom
3. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
4. Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
5. Adamis Pharmaceuticals CEO Provides Update for Shareholders
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
8. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
9. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
10. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
11. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... MISSISSAUGA, ON , July 11, 2014 /CNW/ - ... Canada approved APTIOM TM (eslicarbazepine acetate) for use ... partial-onset seizures in patients with epilepsy who are not ... not indicated for use in patients under 18 years ... the most common neurological disorders and according to Epilepsy ...
(Date:7/10/2014)... Deep Knowledge Ventures last week ... ‘Commercialising Longevity Research’ and welcomed a host of ... Bioscience Innovation Center for the event, organised by ... Ltd. The meeting highlighted the need for both ... age-related disease, as well as the crucial role ...
(Date:7/10/2014)... Angeles, CA (PRWEB) July 10, 2014 ... and Bioanalytical techniques during 18-20 August, 2014 at Double ... critically review the recent developments in Analytical & Bioanalytical ... the globe. , Speaking on this occasion, Dr. Srinubabu ... Analytica Acta conference is a remarkable one in ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a firm ... today announced that it has acquired the Slim-Fast brand ... the business. Terms of the transaction were not disclosed. ... meal replacement business that markets ready-to-drink shakes, powders, bars ... America and in the United ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... URBANA University of Illinois scientists have engineered a new ... the time it took just months ago. That,s a process ... University of Illinois assistant professor of microbial genomics and a ... key is the strain,s ability to ferment cellobiose and galactose ...
... Technologies Corporation (NASDAQ: LIFE ) today announced ... Sciences Conference on Tuesday, September 20 at 8:00am ET. ... will present on behalf of the company. The company ... three weeks following the conference on the Life Technologies, ...
... 2011 GNAX Health , ... proudly announces certification as the first and only healthcare IT ... " services provider. The announcement was made by Mariano Maluf, ... at VMworld2011 , the U.S. conference for VMware technology ...
Cached Biology Technology:IllinoisUC Berkeley discovery turns seaweed into biofuel in half the time 2Life Technologies to Present at the UBS 2011 Global Life Sciences Conference 2GNAX Health Named by VMware as First vCloud® Powered Service Provider in Healthcare IT 2GNAX Health Named by VMware as First vCloud® Powered Service Provider in Healthcare IT 3
(Date:7/10/2014)... July 2, 2014 It is a great ... the appointment of the world-renowned Thoracic and Cardiovascular surgeon, ... Dr. Ginsburg, with over 34 years of ... Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg ... late 1980,s and is considered an expert in the ...
(Date:7/10/2014)... , July 3, 2014 Research and ... of the "Global Gesture Recognition & Touch-Less ... Forecasts to 2020" report to their offering ... Global Gesture Recognition & Touch-Less Sensing Market to ... for a while, but the companies were unable ...
(Date:7/10/2014)... Sweden , July 8, 2014 ... has won a new design win (DW). An Asian OEM ... date for mass production start in August 2014.   ... Asian smartphone OEM, which has a planned date for start ... an initial ramp order of SEK 5M, for delivery in ...
Breaking Biology News(10 mins):Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... funded by the Biotechnology and Biological Sciences Research Council ... immune system genetics, boosting our ability to produce disease- ... published this evening (28 July) in the journal ... Professor Jim Beynon at the University of Warwick, has ...
... (UH) Rainbow Babies and Children,s Hospital are participating in ... AsthmaNet. UH Rainbow, one of the 27 clinical ... of Pittsburgh Medical Center (through a subcontract with Case ... future asthma clinical research studies in children and adults. ...
... The ability to tag proteins with a green fluorescent light ... understanding of protein biology that it earned the scientific teams ... at Weill Cornell Medical College have developed a similar fluorescent ... forms of cellular RNA. In the July 29 issue ...
Cached Biology News:Plant immunity discovery boosts chances of disease-resistant crops 2UH Rainbow Babies and Children's Hospital opens asthma studies 2UH Rainbow Babies and Children's Hospital opens asthma studies 3Breakthrough lights way for RNA discoveries 2Breakthrough lights way for RNA discoveries 3
IHC detection kit for PCNA in cells and tissues...
... Immunogen: Synthetic peptide derived from ... WNT1 protein. Specificity: Reacts with ... Reactivity: Human Mouse (positive controls: ... cell lysates and mouse Mouse-1 cell ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
... [125I] Direct SPA Screening Assay, ... reagents that eliminate lengthy sample extraction ... (optional use).Range: 1.32-84.28 ng/ml (4-256 pmol/ml).Sensitivity: ... at 2-8 C. Category: Drug Screening ...
Biology Products: